Form 4: Entrada Therapeutics Director Peter S. Kim Acquires Additional Shares

Director Peter S. Kim of Entrada Therapeutics, Inc. recently purchased 2,600 shares of common stock at an average price of $13.573 per share.

Summary

• On April 8, 2024, Peter S. Kim, a director of Entrada Therapeutics, Inc., acquired 2,600 shares of the company's common stock.
• The shares were purchased at a weighted average price of $13.573, with individual transactions ranging from $13.49 to $13.78.
• Following the transaction, Kim directly owns 62,936 shares of Entrada Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock purchase. While insider buying can be seen as a positive signal, it's a relatively small transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is required when a company insider (such as a director or officer) buys or sells shares of their company's stock. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive sign of confidence in the company.

Key Dates